Vigencell reported positive top‑line results from a phase II trial of VT‑EBV‑N, an antigen‑specific killer T‑cell therapy targeting Epstein‑Barr virus (EBV) antigens in natural killer/T‑cell lymphoma (NKTCL). The company said it will pursue conditional approval in South Korea based on the data, calling VT‑EBV‑N the first cell therapy to demonstrate efficacy in this indication. Vigencell plans to advance regulatory filings domestically and explore global commercialization given the high unmet need in EBV‑associated NKTCL. The readout underscores growing interest in antigen‑specific adoptive cell therapies beyond CAR T approaches. Clarification: VT‑EBV‑N comprises T cells selected or engineered to recognize EBV antigens frequently expressed in NKTCL tumor cells.